Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Anticalin proteins are currently used as research tools. Diagnostic and therapeutic applications, including the use for targeted drug delivery, are being aimed at.

Type
Public
HQ
Boston, US
Founded
2001
Size (employees)
49 (est)+29%
Website
pieris.com
Pieris Pharmaceuticals was founded in 2001 and is headquartered in Boston, US
Report incorrect company information

Pieris Pharmaceuticals Office Locations

Pieris Pharmaceuticals has an office in Boston
Boston, US (HQ)
255 State St
Show all (1)
Report incorrect company information

Pieris Pharmaceuticals Financials and Metrics

Pieris Pharmaceuticals Financials

Pieris Pharmaceuticals's revenue was reported to be $5.83 m in FY, 2016 which is a 98.9% increase from the previous period.
USD

Revenue (Q2, 2017)

1.9 m

Net income (Q2, 2017)

(10.1 m)

EBIT (Q2, 2017)

(7.9 m)

Market capitalization (5-Feb-2018)

383.1 m

Cash (2-Feb-2018)

50.3 m
Pieris Pharmaceuticals's current market capitalization is $383.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

5.4 m2.9 m5.8 m

Revenue growth, %

(45%)99%

General and administrative expense

7 m8.4 m8.9 m

R&D expense

5.6 m8.2 m19.7 m
Quarterly
USDQ1, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

217.6 k160.2 k414.6 k1.2 m1.1 m785 k1.3 m1.9 m

General and administrative expense

2.4 m2 m2.2 m2 m2.4 m2.3 m4 m4.3 m

R&D expense

1.5 m1.7 m2.1 m3.7 m4.5 m4.6 m5.4 m5.4 m

Operating expense total

13.9 k3.9 m3.7 m4.3 m5.6 m6.9 m7 m9.3 m9.7 m
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

18.5 m29.3 m29.4 m

Accounts Receivable

5.7 m995 57.6 k

Inventories

2.3 m3.3 m

Current Assets

19.8 m31.7 m32.7 m
Quarterly
USDQ2, 2014Q1, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

13.2 m10 m32.3 m31.2 m40.4 m36.6 m55.2 m50.3 m

Accounts Receivable

39 k48.5 m

Current Assets

15 m12.6 m34.2 m34.9 m43.9 m41.1 m58.8 m102.7 m

PP&E

1.8 m1.8 m1.9 m2.2 m2.4 m2.4 m3 m3.1 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(9.8 m)(14.1 m)(22.8 m)

Depreciation and Amortization

367 k307.9 k361.4 k

Inventories

4 k(136.3 k)127.5 k

Accounts Payable

1.1 m(90.9 k)1.4 m
Quarterly
USDQ1, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(13.9 k)(3.7 m)(3.5 m)(3.9 m)(4.2 m)(5.9 m)(6.2 m)(8 m)

Accounts Payable

1.5 m2.1 m1.1 m1.7 m1.6 m4.5 m3.3 m

Cash From Operating Activities

(13.9 k)

Cash From Financing Activities

3 k
USDY, 2017

Financial Leverage

11.4 x
Show all financial metrics
Report incorrect company information